参一胶囊联合内皮抑制素对晚期非小细胞肺癌化疗的辅助疗效分析  

Analysis of the therapeutic efficacy of chemotherapy combined with Shenyi capsule and human endostatin for advanced non-small cell lung cancer

作　　者：王琳[1] 孟丽娟[1] 樊卫飞[1] 蒲骁麟[1] 许菊青 王峻[1] 潘士勇[2] 

机构地区：[1]江苏省老年医院血液肿瘤科,江苏省南京市210024 [2]中国人民解放军南京军区南京总医院保健科,江苏省南京市210002

出　　处：《实用老年医学》2015年第3期204-206,共3页Practical Geriatrics

基　　金：江苏省中医药局科技项目(LZ11089)

摘　　要：目的观察参一胶囊、内皮抑制素联合化疗治疗晚期非小细胞肺癌的疗效和不良反应。方法46例老年晚期非小细胞肺癌患者,随机分为治疗组和对照组。治疗组24例,治疗方案为参一胶囊＋恩度＋化疗（化疗方案为多西紫杉醇联合卡铂）。对照组22例,仅采用化疗（化疗方案为多西紫杉醇联合卡铂）,3-4周为1周期。所有患者均完成≥2周期治疗。结果治疗组和对照组治疗有效率（RR）分别为41.6%、40.9%,疾病控制率分别为75%、68.2%;无进展生存时间（PFS）分别为6.5月和5.1月,患者1年生存率分别为79.1%和63.6%,差异均无统计学意义（P〉0.05）。2组患者对不良反应均可耐受,治疗组化疗耐受性以及生存质量均高于对照组,差异有统计学意义（P〈0.05）。结论参一胶囊＋恩度＋化疗对于延长老年晚期肺癌患者的PFS以及一年生存率有一定趋势;化疗联合参一胶囊以及恩度可以减轻化疗相关不良反应,改善患者生存质量。Objective To analyze the therapeutic efficacy of chemotherapy combined with Shenyi capsule and human endostatin in the elderly patients with advanced non-small cell lung cancer（ NSCLC）. Methods Forty-six elderly patients with NSCLC were divided into treatment group and control group randomly. In treatment group,24 cases received chemotherapy（ docetaxel plus carboplatin） and Shenyi capsule and human endostatin. In control group,22 cases only received chemotherapy（ docetaxel plus carboplatin）. All patients received at least 2 cycles of treatment（ 3-4 weeks as a cycle）. Results In treatment group and control group,the effective rate（ RR） was 41. 6%,40. 9% respectively,and the disease control rate（ DCR） was 75%,68. 2% respectively,the median PFS was 6. 5,5. 1 months respectively,and the oneyear survival rate was 79. 1%,63. 6% respectively（ P〉0. 05）. Treatment group showed less toxicity and better quality of life（ P〈0. 05）. Conclusions Elderly patients with NSCLC can benefit from chemotherapy combined with Shenyi capsule and human endostatin,with less toxicity and better quality of life.

关 键 词：非小细胞肺癌 参一胶囊 化疗 内皮抑制素 

分 类 号：R734.2[医药卫生—肿瘤]